Autologous tumor lysate antigens (ATLA)

Autologous tumor lysate antigens represent the entire collection of proteins, including neoantigens and overexpressed self-antigens, derived directly from a patient's surgically resected tumor (Liau et al., 2023; NCI, 2024). These antigens serve as the foundation for personalized cancer vaccines, where the lysate is typically pulsed onto dendritic cells to stimulate a multi-antigenic, polyclonal immune response (PubMed, 2021). This broad-spectrum targeting is designed to address the inherent heterogeneity of tumors and minimize the risk of antigen escape, a common failure mode in single-antigen immunotherapies (Frontiers in Immunology, 2022). Clinically, this approach is most notably applied in the treatment of glioblastoma multiforme and other solid tumors, where it aims to enhance the recruitment and activation of cytotoxic T-lymphocytes within the tumor microenvironment (Journal of Clinical Oncology, 2023). While generally safe, the primary challenges involve the requirement for sufficient tumor tissue and the complex, patient-specific manufacturing process required for each individual (Nature Communications, 2020).

Other names

Autologous tumor cell lysateWhole tumor lysatePatient-specific tumor antigensTumor-derived antigensAutologous tumor-associated antigens

Induction of a polyclonal immune response by presenting a broad spectrum of patient-specific tumor antigens (including neoantigens and overexpressed self-antigens) to T-cells via dendritic cells or other antigen-presenting cells to overcome tumor heterogeneity.